Differential Immune Modulation With Carbon-Ion Versus Photon Therapy.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 03 2021
Historique:
received: 16 07 2020
revised: 21 09 2020
accepted: 28 09 2020
pubmed: 17 11 2020
medline: 22 7 2021
entrez: 16 11 2020
Statut: ppublish

Résumé

Radiation therapy (RT) modulates the immune characteristics of the tumor microenvironment (TME). It is not known whether these effects are dependent on the type of RT used. We evaluated the immunomodulatory effects of carbon-ion therapy (CiRT) compared with biologically equivalent doses of photon therapy (PhRT) on solid tumors. Orthotopic 4T1 mammary tumors in immunocompetent hosts were treated with CiRT or biologically equivalent doses of PhRT. Seventy-two hours after RT, tumors were harvested and the immune characteristics of the TME were quantified by flow cytometry and multiplex cytokine analyses. PhRT decreased the abundance of CD4+ and CD8+ T cells in the TME at all doses tested, with compensatory increases in proliferation. By contrast, CiRT did not significantly alter CD8+ T-cell infiltration. High-dose CiRT increased secretion of proinflammatory cytokines by tumor-infiltrating CD8+ T cells, including granzyme B, IL-2, and TNF-α, with no change in IFN-γ. Conversely, high-dose PhRT increased CD8+ T-cell secretion of IFN-γ only. At most of the doses studied, PhRT increased proliferation of immunosuppressive regulatory T cells; this was only seen with high-dose CiRT. Cytokine analyses of bulk dissociated tumors showed that CiRT significantly increased levels of IFN-γ, IL-2, and IL-1β, whereas PhRT increased IL-6 levels alone. At low doses, lymphocytes differ in their sensitivity to CiRT compared with PhRT. Unlike PhRT, low-dose CiRT is generally lymphocyte-sparing. At higher doses, CiRT is a more potent inducer of proinflammatory cytokines and merits further study as a modulator of the immunologic characteristics of the TME.

Identifiants

pubmed: 33190969
pii: S0360-3016(20)34355-8
doi: 10.1016/j.ijrobp.2020.09.053
pii:
doi:

Substances chimiques

Interleukin-1beta 0
Interleukin-2 0
Interleukin-6 0
Tumor Necrosis Factor-alpha 0
Interferon-gamma 82115-62-6
Granzymes EC 3.4.21.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

813-818

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Catherine S Spina (CS)

Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York; Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York.

Chizuru Tsuruoka (C)

Department of Radiation Effects, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Japan.

Wendy Mao (W)

Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York.

M Masaaki Sunaoshi (MM)

Department of Radiation Effects, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Japan.

Matthew Chaimowitz (M)

Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York.

Yi Shang (Y)

Department of Radiation Effects, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Japan.

David Welch (D)

Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York.

Yi-Fang Wang (YF)

Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York.

Nicholas Venturini (N)

Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York.

Shizuko Kakinuma (S)

Department of Radiation Effects, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Japan.

Charles G Drake (CG)

Department of Radiation Oncology, Columbia University Irving Medical Center, New York, New York; Department of Urology, Columbia University Medical Center, New York, New York; Department of Hematology Oncology, Columbia University Medical Center, New York, New York. Electronic address: cgd2139@cumc.columbia.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH